Free Trial

MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Quarterly Earnings Results

MoonLake Immunotherapeutics logo with Medical background
Remove Ads

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09), Zacks reports.

MoonLake Immunotherapeutics Trading Down 0.0 %

Shares of MoonLake Immunotherapeutics stock traded down $0.01 during trading hours on Friday, hitting $41.76. 302,843 shares of the company were exchanged, compared to its average volume of 439,783. The business has a 50-day moving average of $46.49 and a 200-day moving average of $48.94. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28.

Analysts Set New Price Targets

Several research firms have commented on MLTX. Wedbush reaffirmed an "outperform" rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday. The Goldman Sachs Group dropped their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Needham & Company LLC increased their price target on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of "Buy" and an average target price of $83.20.

Remove Ads

View Our Latest Analysis on MLTX

MoonLake Immunotherapeutics Company Profile

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Recommended Stories

Earnings History for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Should You Invest $1,000 in MoonLake Immunotherapeutics Right Now?

Before you consider MoonLake Immunotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.

While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

These Are the 3 Stocks Most Likely to SPLIT in 2025

These Are the 3 Stocks Most Likely to SPLIT in 2025

MarketBeat analyst Thomas Hughes breaks down why companies split their stock and reveals his top three picks most likely to split next year.

Related Videos

7 Inflation-Proof Stocks to Protect Your Portfolio
7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads